Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 7/20 | 0.53 |
| ▸ | THRB | P10828 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7274368 | 0.91 | THRB (0.42) | THRATHRBALDH1A1LMNAMEN1 | |
| SCHEMBL7282348 | 0.86 | THRA (0.49) | THRATHRBALDH1A1LMNAMEN1 | |
| SCHEMBL7275728 | 0.85 | THRB (0.36) | THRATHRBKDM4EALDH1A1LMNA | |
| SCHEMBL10414279 | 0.84 | ALDH1A1 (0.44) | THRATHRBALDH1A1LMNAMEN1 | |
| SCHEMBL7273788 | 0.81 | THRB (0.36) | THRATHRBKDM4EALDH1A1LMNA | |
| SCHEMBL7281471 | 0.79 | KDM4E (0.33) | THRATHRBKDM4EALDH1A1LMNA | |
| SCHEMBL7283741 | 0.76 | THRA (0.51) | THRATHRBALDH1A1LMNAGAA | |
| SCHEMBL8997459 | 0.74 | THRB (0.39) | THRATHRBALDH1A1GAACAPN1 | |
| SCHEMBL7285428 | 0.74 | THRA (0.49) | THRATHRBALDH1A1LMNA | |
| SCHEMBL7274691 | 0.72 | THRA (0.34) | THRATHRBALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0809490-A4 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0871436-A4 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0835104-A4 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0871436-A1 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0835104-A1 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-15 | — | — | EP | disclosed |
| EP-0809490-A1 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1997002023-A1 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-23 | — | — | WO | disclosed |
| WO-1997002024-A1 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-23 | — | — | WO | disclosed |
| EP-0728482-A2 | Use of hcp specific compounds to enhance erythropoiesis | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-28 | — | — | EP | disclosed |
| EP-0727211-A1 | Use of src SH2 specific compounds to treat a bone resorption disease | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-21 | — | — | EP | disclosed |
| WO-1996024343-A1 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-15 | — | — | WO | disclosed |
| US-5061798-A | Intermediates in the formation of synthetic hormones, mimic effects of thyroid hormones; little or no effect on the heart | SMITH KLINE & FRENCH LABORATORIES, LTD. (GB) | 1991-10-29 | — | — | US | disclosed |
| EP-0188351-B1 | CHEMICAL COMPOUNDS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1991-03-13 | — | — | EP | disclosed |
| US-4910305-A | Containing a protected 4-hydroxyphenyl | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-03-20 | — | — | US | disclosed |
| US-4826876-A | WITHOUT EFFECT ON HEART | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-05-02 | — | — | US | disclosed |
| US-4766121-A | NOT AFFECTING THE HEART | SMITH KLINE & FRENCH LABORATORIES LTD. (GB) | 1988-08-23 | — | — | US | disclosed |